News

Communique #67

7 July, 2022

Click for the latest Taskforce news: 

Communique

Communique #48

5 August, 2021

WEEK IN REVIEW Taskforce amends remarks for Tocilizumab in response to critical shortage This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage...

Communique

Guidelines update, v41.1

15 July, 2021

Version 41.1 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of six new studies on disease-modifying treatments. Convalescent plasma - two...

News

Guidelines update, v38.3

13 May, 2021

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   Convalescent plasma...

News

Guidelines update, v38.1

29 April, 2021

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   - Lopinavir-ritonavir...

News

Communique #41

1 April, 2021

WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...

Communique

Guidelines update, v35.2

11 March, 2021

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Tocilizumab - The reference for one included study (Wang et al.) was...

News

Guidelines update, v35.1

4 March, 2021

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...

News

Weekly Communique #10

18 June, 2020

WEEK IN REVIEW Dexamethasone and RECOVERY Trial  Oxford University's media release detailing preliminary results from the dexamethasone arm of the RECOVERY Trial dominated international headlines. In response, the...

Communique